FX 909
Alternative Names: FTX-6746; FX-909Latest Information Update: 28 Oct 2026
At a glance
- Originator Flare Therapeutics
- Class Antineoplastics; Benzonitrile; Fluorobenzenes; Ketones; Quinolines; Small molecules; Sulfones
- Mechanism of Action Peroxisome proliferator-activated receptor gamma antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bladder cancer; Solid tumours
- No development reported Urogenital cancer
Most Recent Events
- 28 Oct 2026 No recent reports of development identified for phase-I development in Urogenital-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)
- 28 Oct 2026 No recent reports of development identified for phase-I development in Urogenital-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO, Tablet)
- 07 Jul 2026 Preclinical trials in Bladder cancer in USA (PO) prior to July 2026 (Flare Therapeutics pipeline, July 2026)